Lilly's Omvoh (mirikizumab-mrkz) approved by U.S. FDA as a single-injection maintenance regimen in adults with ulcerative colitis

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) approved a ...
MPR

FDA Approves Omvoh Single-Injection Maintenance Regimen for Ulcerative Colitis

The new approval allows patients to transition to a single 200mg subcutaneous injection once every 4 weeks, following completion of the induction phase.
Nasdaq

BD Expands Capacity for Advanced Prefillable Syringes and Enhances Injection Experience for the Next Generation of Biologics

LE PONT-DE-CLAIX, France, Sept. 18, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the commercial release of the BD Neopak™ ...
PharmiWeb

Global Prefilled Syringes Market: Self-Injection Devices Driving Market Expansion by 2027

The Global Prefilled Syringes Market is expected to witness a high single-digit growth rate by 2027. The growth of the prefilled syringes market is driven by an increasing prevalence of diverse ...

Dangerous or life-saving? Why drug programs that stop disease are under fire.

EVANSVILLE, Ind. - Lavender Timmons popped the trunk of her weather-beaten 2007 Ford Focus parked near the city’s homeless ...
PharmExec

FDA Approves Single-Injection, Once-Monthly Maintenance Regimen for Lilly’s Omvoh in Ulcerative Colitis

The FDA has approved a new single-injection, once-monthly maintenance regimen for Eli Lilly’s Omvoh (mirikizumab-mrkz), ...